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Summary
Dietary iron intake and systemic iron balance are implicated in colorectal cancer (CRC) 
development, but the means by which iron contributes to CRC are unclear. Gene expression and 
functional studies demonstrated that the cellular iron importer, divalent metal transporter 1 
(DMT1), is highly expressed in CRC through hypoxia inducible factor 2α-dependent 
transcription. Colon-specific Dmt1 disruption resulted in a tumor-selective inhibitory effect of 
*Correspondence author: Tel: +1 734 6150567; Fax: +1 734 9368813; shahy@umich.edu. 
Authorship Contributions
Conception and design: X. Xue, E.R Fearon, M. Dame, J. Varani, D. Brenner, and Y.M. Shah.
Development of methodology: X. Xue, L. Xie, S. Ramakrishnan, K. Weisz, D. Triner J. Varani, M. Dame, C. Carter-Su, T.D Wang, 
and Y.M. Shah.
Acquisition of data: X. Xue, L. Xie, S. Ramakrishnan, K. Weisz, D. Triner, D. Attili, M. Zhan, K. Hardiman, J. Varani, M. Dame, A. 
Pant and Y.M. Shah.
Analysis and interpretation of data: X. Xue, E.R Fearon, M. Dame, J. Varani, D. Brenner, B. Győrffy, T.D Wang, and Y.M. Shah.
Writing, review, and/or revision of the manuscript: X. Xue, S. Ramakrishnan, K. Weisz, D. Triner, L. Xie, B. Győrffy, M. Zhan, C. 
Carter-Su, K. Hardiman, M. Dame, J. Varani, D. Brenner, E.R. Fearon and Y.M. Shah
Study supervision: Y.M. Shah
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
Cell Metab. Author manuscript; available in PMC 2017 September 13.
Published in final edited form as:
Cell Metab. 2016 September 13; 24(3): 447–461. doi:10.1016/j.cmet.2016.07.015.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
proliferation in mouse colon tumor models. Proteomic and genomic analysis identified an iron-
regulated signaling axis mediated by cyclin dependent kinase 1 (CDK1), JAK1 and STAT3 in CRC 
progression. A pharmacological inhibitor of DMT1 antagonized the ability of iron to promote 
tumor growth in a CRC mouse model and a patient-derived CRC enteroid orthotopic model. Our 
studies implicate a growth-promoting signaling network instigated by elevated intracellular iron 
levels in tumorigenesis, offering molecular insights into how a key dietary component may 
contribute to CRC.
eTOC
Although high iron levels, including dietary red meat, have been associated with increased cancer 
risk, the underlying mechanisms are unknown. Xue et al. show that the iron importer DMT1 is 
responsible for the intracellular iron accumulation in colorectal cancer and that iron activates 
CDK1-JAK1-STAT3 signaling to support tumor cell proliferation.
Introduction
Colorectal cancer (CRC) is the third most common type of cancer and the third leading 
cause of cancer-related death in the United States (Siegel et al., 2014). The mutations 
identified in CRC alter signaling pathways and gene expression as well as metabolite 
requirements, allowing cancer cells to acquire a growth and survival advantage. The 
metabolic differences between normal and cancer cells are being interrogated to uncover 
potential therapeutic targets and approaches. Nevertheless, at present, little is known about 
micronutrient metabolism in cancer. Several large epidemiological studies demonstrate a 
direct correlation between dietary iron intake and/or systemic iron levels and cancer risk in 
several cancers including CRC (Merk et al., 1990; Nelson, 2001; Osborne et al., 2010; 
Zacharski et al., 2008). Moreover, iron overload caused by mutations in the HFE gene (HFE 
C282Y and H63D homozygous) and/or high dietary heme iron consumption (red meat) is 
associated with increased CRC risk (Cross et al., 2010; Osborne et al., 2010). Consistent 
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with the human epidemiological data, in selected mouse models of intestinal tumor 
development, the tumor-prone mice fed low-iron diet had reduced tumor multiplicity, size, 
and progression; whereas, the mice fed high-iron diet had enhanced tumor phenotypes 
(Radulescu et al., 2012; Xue et al., 2012). The expression of multiple iron metabolism and 
transport genes is significantly altered in CRC relative to normal colon epithelium, leading 
to an accumulation of intratumoral iron (Brookes et al., 2006; Xue and Shah, 2013b; Xue et 
al., 2012). Some studies have shown iron can increase oxidative stress and WNT signaling 
(Brookes et al., 2006; Seril et al., 2003). Despite the data implicating iron is involved in 
colon tumorigenesis, the mechanisms through which iron metabolism might contribute to 
the development and progression of CRC remains unknown. In addition, it is unclear if 
targeting intratumoral iron might be an effective treatment or prevention strategy for CRC.
Understanding the role of intratumoral iron in colon tumorigenesis in vivo has been limited 
in part because most of the previously employed mouse intestinal tumor models, such as 
ApcMin/+ mice, manifest mainly small intestinal adenomas (Hinoi et al., 2007). The small 
intestine and colon have markedly different roles in iron homeostasis. The small intestine is 
essential in maintaining intestinal iron absorption and systemic iron homeostasis. Thus, 
small intestine-preferential or intestinal-wide disruption of iron transporters and exporters 
lead to systemic and extensive changes in iron homeostasis (Donovan et al., 2005; Gunshin 
et al., 2005). Here, to address the role of iron in colon tumorigenesis, colon-selective gene 
targeting, and patient-derived colorectal tumor enteroids were used. We find that colorectal 
tumor epithelium, but not adjacent normal tissues, is dependent on elevated intracellular iron 
levels for growth, mediated via hypoxia inducible factor (HIF)-2α dependent regulation of 
the apical iron transporter divalent metal transpoter-1 (DMT1, also known as solute carrier 
family [SLC] 11, member 2 [SLC11A2]). In-depth characterization of the iron interactome 
in colon tumors highlighted a key-signaling axis. Iron increases cyclin-dependent kinase 
(CDK) 1 which activates the Janus kinase (JAK) 1/signal transducer and activator of 
transcription (STAT) 3 signaling pathway.
Results
Tumor epithelial DMT1 is increased in CRC patients
Prior work with a small collection of CRC patient samples indicated that expression of 
selected iron transport genes were increased in tumor tissues (Brookes et al., 2006). To 
investigate further potential factors and mechanisms involved in intratumoral iron 
accumulation in CRC, analysis of iron transport genes was undertaken using RNA-
sequencing data from The Cancer Genome Atlas (TCGA) CRC analyses. This dataset 
contains over 200 CRC and adjacent normal epithelium samples (Cancer Genome Atlas, 
2012). Several genes critical for iron regulation were differentially expressed, with reduced 
expression of aconitase 1 (ACO1, also known as IRP1), cytochrome b reductase 1 
(CYBRD1), ferritin heavy chain (FTH1), hephaestin (HEPH) and ferroportin (FPN, also 
known as SLC40A1), and increased expression of hepcidin antimicrobial peptide (HAMP), 
hemochromatosis Type 2 Protein (HFE2), iron-responsive element binding protein 2 
(IREB2), SLC11A1, DMT1 and transferrin receptor (TFRC) (Figure 1A). The changes 
observed in DMT1 were further studied in 8 primary CRCs and paired adjacent normal 
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epithelium (Figure 1B). Indeed, increased DMT1 expression in CRC compared to adjacent 
normal tissue is a consistent change that has been observed in several studies (Brookes et al., 
2006; Xue and Shah, 2013b; Xue et al., 2012). However, it is unclear if protein expression 
correlates with increased DMT1 mRNA and if DMT1 is localized to the tumor epithelium. 
We found the two-fold change in mRNA reflects a robust change in DMT1 protein 
expression, which goes from nearly undetectable to highly expressed and localized to the 
apical membrane in colorectal tumor epithelium (Figure 1C and 1D). These data suggest that 
DMT1 expression is increased and apical iron transport would be enhanced in CRC.
Colon-selective disruption of DMT1 decreases sporadic and colitis-associated colon 
tumors
To further address whether local colonic iron has an impact on tumor growth, Dmt1F/F mice 
were crossed with colon-selective caudal type homeobox 2 (CDX2) P-NLS Cre mice (Hinoi 
et al., 2007) to disrupt DMT1 in the colon (CDX2 Dmt1F/F) (Figure S1A). Colon-selective 
disruption of DMT1 did not result in a systemic or tissue-specific decrease of iron (Figure 
S1B and S1C). Body weights, colon length, and Ki67 staining were not different under basal 
conditions or following DSS-induced injury and regeneration compared with wild-type 
littermates (Figure S1D–S1G). These findings demonstrate that DMT1 function is not 
essential in the colon. To evaluate the role of DMT1 in a colon tumorigenesis model, the 
CDX2 Dmt1F/F mice were crossed to ApcF/+ mice (CDX2 Dmt1F/F/ApcF/+). This is a colon-
preferential tumor model (Hinoi et al., 2007). DMT1 disruption in this tumor model led to 
significantly reduced tumor number, tumor burden, and tumor cell proliferation (Figure 2A–
2D). CDX2-mediated Cre recombination can be seen as early as E9.5 in the caudal region of 
embryos (Hinoi et al., 2007). No clear colonic developmental issues were observed in the 
CDX2 Dmt1F/F mice. However, to further confirm the role of DMT1 in colon tumorigenesis 
temporally and conditionally, Dmt1F/F mice were crossed with a colon-specific CDX2-
CreERT2 mouse (CDX2ERT2 Dmt1F/F). Similarly, colon-specific disruption of DMT1 after 
tamoxifen (TAM) injection did not result in systemic or tissue-specific decreases in iron 
(Figure S1H–S1J). Also, susceptibility to DSS-induced acute colitis, as reflected by body 
weight, colon length, Ki67 staining, and histological analysis was not altered compared to 
littermate control animals (Figure S1K–S1N). CDX2ERT2 ApcF/+ mice, following TAM 
treatment have a long latency period for colon tumor development and only a limited 
number of tumors arise spontaneously (Feng et al., 2013). This is likely due in part to a 
lower TAM-induced CDX2-CreERT2-mediated targeting of one Apc allele in colon 
epithelium compared to the efficiency of Apc inactivation mediated by CDX2-NLS Cre. 
However, treatment of the CDX2ERT2 ApcF/+ mice with DSS resulted in enhanced tumor 
formation, and disruption of colonic DMT1 significantly reduced the DSS-induced tumor 
development and iron accumulation (Figure S2A). The expression of DMT1 in tumors from 
colon-specific DMT1 inactivation was significantly reduced, albeit not to levels observed 
with the CDX2-Cre (Figure S2B and 2E). Tumor number, tumor size, and tumor cell 
proliferation in mice with colon-specific DMT1 inactivation was significantly reduced when 
maintained on an iron replete diet (35 mg/kg iron, 35 Fe) (Figure 2F and 2G). Moreover, we 
demonstrate that high-iron diet (1000 mg/kg iron, 1000 Fe) conditions increased tumor 
number and burden compared to iron-replete diet and this potentiation is also attenuated 
following DMT1 disruption (Figure 2F and 2G). Mice with a single copy deletion of DMT1 
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(CDXERT2Dmt1F/+/ApcF/+) had similar basal expression levels of Dmt1 compared to wild 
type littermates, but the increase of Dmt1 mRNA expression that is observed in tumors was 
lost (Figure 2E). A decrease in tumor number, tumor size, and tumor cell proliferation was 
observed in these mice, demonstrating that the increase in Dmt1 observed in tumor tissue is 
critical to drive tumorigenesis (Figure 2F and 2G). Consistent with the Ki67 staining results, 
BrdU incorporation assays showed that tumor cell proliferation was decreased when DMT1 
was disrupted (Figure S2C). In contrast, tumor apoptosis, vascularization and macrophage 
infiltration were not altered by DMT1 inactivation (Figure S2C and S2D). These results 
suggest intratumoral iron accumulation via DMT1 is an essential mechanism for neoplastic 
but not normal colon epithelium.
HIF-2α is essential in the activation of DMT1 in colon tumors
Previously, we have shown DMT1 is a direct target gene of HIF-2α (Shah et al., 2009). The 
increase in DMT1 in tumors has been suggested to be dependent on the β-catenin pathway 
(Radulescu et al., 2012). To further understand if HIF-2α is also involved, an intestine or 
colon specific disruption of HIF-2α in the Apcmin/+ mouse intestinal tumor model and the 
colon-specific sporadic CRC model were assessed. Interestingly, disruption of HIF-2α 
significantly reduced tumoral DMT1 (Figure 3A and 3B). In addition, colon-specific 
disruption of Hif-2α in ApcF/+ tumor mouse model led to significantly reduced tumor 
number and intratumoral iron accumulation (Figure 3C and 3D). Thus, the lack of DMT1 
induction following HIF-2α disruption may contribute to the reduced tumor burden. 
However, to be noted, other mechanisms may also explain or contribute to the reduction of 
tumor burden after loss of HIF-2α (Xue and Shah, 2013a). Mutations in oncogenes and 
tumor-suppressor genes such as APC, KRAS, TP53, PIK3CA as well as MYC expression 
have been well characterized during the progression of CRC (Cancer Genome Atlas, 2012). 
To understand if these defects contribute to DMT1 induction by HIF-2α, DMT1 promoter 
reporter assays were undertaken (Figure 3E–3H). Expression of β-catenin and c-MYC, but 
not control vector (pcDNA3.1), KRAS, P53 and PI3K, significantly increased HIF-2α 
mediated transcriptional activation of DMT1 (Figure 3E). These data are consistent with 
previous work demonstrating a role for β-catenin and c-MYC in mediating DMT1 increase 
in CRC (Radulescu et al., 2012). However, these data clearly demonstrate the central role of 
HIF-2α in the transcriptional regulation of DMT1. To fully elucidate genes critical for 
DMT1 activation, a high-throughput screening approach was used. HCT116 cells 
overexpressing HIF-2α and DMT1 promoter luciferase were tested with a siRNA-based 
screening using a druggable target library (Figure 3I). A panel of 230 genes were identified 
that led to more than 90% reduction of HIF-2α-induced DMT1 promoter activity. These 
genes were further filtered with the TCGA gene expression datasets and genes predictive of 
relapse free survival were validated with independent siRNAs, which identified a group of 
15 genes involved in DMT1 activation. Together, these results provide insights for the 
mechanism of DMT1 activation and provide potential targets to limit DMT1 activation in 
tumors.
Iron is essential in JAK-STAT3 signaling in colon cancer
Previous reports have demonstrated that iron can increase WNT signaling and iron chelation 
can potently inhibit WNT signaling (Brookes et al., 2008; Song et al., 2011). Thus, we 
Xue et al. Page 5
Cell Metab. Author manuscript; available in PMC 2017 September 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
investigated whether activation of WNT signaling could be the major mechanism for iron-
driven colon tumorigenesis. Surprisingly and in contrast to the previous reports, iron 
treatment did not increase WNT signaling activity in nine different colon cancer cell lines 
studied (Figure S3A). To identify other mechanisms by which intratumoral iron regulates 
cellular proliferation and colorectal tumorigenesis, whole genome expression profiles were 
assessed in colorectal tumor tissue of CDX2 Dmt1F/F/ApcF/+ and their littermate controls. 
Several immune and inflammatory NF-κB responses were enriched in the tissues, based on 
gene set enrichment analysis (GSEA) (Figure 4A). Genes critical in the inflammatory 
response were confirmed by qPCR (Figure 4B). Iron did not directly activate NF-κB 
signaling in CRC cells, suggesting that other inflammatory transcription factors may be 
regulated by iron (Figure S3B and S3C). Mining the TCGA gene expression dataset in 
conjunction with the TCGA reverse phase protein arrays (Cerami et al., 2012) uncovered a 
connection indicating that expression levels of p-STAT3 were positively correlated with the 
expression level of iron transporters in colorectal tumors (Figure 5A). These data are 
consistent with the GSEA analysis in which several of the inflammatory genes identified 
were also STAT3-regulated target genes (Jarnicki et al., 2010). To further understand if 
STAT3 activation is dependent on DMT1 expression, p-STAT3 levels were assessed in 
tumors from colon-specific Dmt1 knockout mice compared to littermate controls. Western 
blotting analysis and immunofluorescence staining of p-STAT3 clearly demonstrated that 
STAT3 activation was significantly attenuated in tumors where DMT1 was disrupted 
compared to tumors with intact DMT1 expression (Figure 5B and 5C). Moreover, treating 
colon-derived cell lines with high iron led to a dose- and time-dependent activation of 
STAT3 (Figure S4A–S4C). STAT3 can be activated by cytokines such as interleukin (IL) 6 
via JAK signaling (O’Shea et al., 2013; Yu et al., 2009; Zhong et al., 1994) (Figure S4D). 
JAK1 and JAK2, but not JAK3, could potently activate STAT3 in two CRC-derived cell 
lines, and this activation was partially reversed by the iron chelator deferoxamine (DFO) 
(Figure 5D). DFO also decreased IL6-induced p-STAT3, whereas iron supplementation or 
DMT1 overexpression activated p-STAT3, in a JAK-dependent manner (Figure 5E–5G). 
Similarly, the STAT3 inhibitor (STAT3i) S3I-201 also abolished iron- and IL6-activated p-
STAT3 (Figure 5H and S4E). To test whether STAT3 is critical for iron-driven tumor growth 
in vivo, we optimized a dose of STAT3i, which efficiently inhibited p-STAT3 in the 
dysplastic colon tissues from Apc-disrupted mice, but not p-STAT3 in normal colon tissues 
from wild-type littermate controls (Figure S4F). STAT3i was then tested in an iron-induced 
colorectal tumor model, whereby CDX2ERT2 ApcF/+ tumor mouse model was placed on 35 
Fe or 1000 Fe with or without STAT3i. The 35 Fe was used to assess the baseline STAT3 
activity and the 1000 Fe was used to evaluate the role of STAT3i in iron-dependent colon 
tumorigenesis. High-iron treatment robustly increased colon tumor formation, tumor 
number, tumor size, tumor burden and tumor cell proliferation in this colitis-associated 
tumor mouse model (Figure 5I, 5J and S4G). STAT3i treatment dramatically reduced colon 
tumorigenesis in the high-iron treated mice. To test the potential translational application of 
STAT3 inhibition, the effect of STAT3 knockdown was assessed in patient-derived tumor 
enteroid models. Patient-derived colorectal tumor enteroids are an ideal model to study the 
effect of iron on intestinal epithelial cells. These cell models resemble colorectal tumors 
with respect to the spectrum of mutations that are observed (van de Wetering et al., 2015). 
The three-dimensional (3D) models show cell polarization, with apical localization of the 
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iron transporter DMT1 and preserved tight junctions (Figure S5A), and the enteroid lines 
can survive long-term in defined serum- and transferrin iron-free conditions. To demonstrate 
that iron is essential for the growth of the tumor enteroids, two patient-derived enteroid lines, 
one isolated from a primary adenoma and the other from an adenocarcinoma were assessed. 
Equal number of enteroids were plated and established. The enteroids were treated with 
DFO. A dose-dependent decrease in the size of adenoma and adenocarcinoma enteroid was 
observed (Figure S5B). Ki67 staining confirmed a significant decrease in proliferation 
following DFO treatment. To assess the direct effect of apical iron transport, the enteroids 
were grown in iron-reduced RPMI 1640 media and supplemented with ferrous sulfate (FS, 
10 or 100 μM) (Figure S5C). The size and cell proliferation of the FS-treated enteroids were 
robustly increased, compared to the untreated enteroids. This provides an optimal model to 
study downstream pathways essential in iron-induced growth. Stable tumor enteroids with 
STAT3 knockdown (shSTAT3) were confirmed by qPCR and Western blot analysis (Figure 
5K). Consistent with the STAT3 inhibitor study, the growth of tumor enteroids was increased 
by iron treatment, whereas knockdown of STAT3 reduced the iron-enhanced growth and 
proliferation of the tumor enteroids (Figure 5L). These data demonstrate that activation of 
JAK-STAT3 signaling is essential for the effect of iron in enhancing colon tumorigenesis.
Iron-dependent CDK1 kinase activity is critical for JAK1-STAT3 activation
Our data has demonstrated that iron is essential and sufficient to activate STAT3 signaling. 
Iron is known to generate reactive oxygen species (ROS) through the Fenton reaction and 
oxidative stress is a known trigger for STAT3 activation (Carballo et al., 1999; Dixon and 
Stockwell, 2014). However, antioxidants such as butylated hydroxyanisole (BHA) and N-
Acetyl-L-cysteine (NAC) could not inhibit the iron-mediated activation of STAT3 (Figure 
S5D). Furthermore, ROS levels, nitrosative marker nitrotyrosine and lipid peroxidation 
marker 4-Hydroxynonenal (4-HNE) in colon tumors were not changed in mice with colon-
specific disruption of Dmt1 compared to littermate control (Figure S5E and S5F). It is 
known that divalent metals such as magnesium (Mg) can directly associate with kinases and 
are critical for their function (Bao et al., 2011). To identify intracellular proteins that may be 
involved in iron signaling, ferrous iron-coated or metal-free beads were utilized. Several 
proteins will bind to beads coated with iron non-specifically through charge interactions, 
however we confirmed that the approach could recover transferrin, a known iron-interacting 
protein (Figure S6A). To identify additional proteins that could bind to iron, ferrous iron-
coated or metal-free beads were incubated with HCT116 or SW480 cell lysates and 
associated proteins were identified by a mass spectrometry-based proteomics approach 
(Figure 6A). A total of 169 proteins including 17 kinases were identified and 7 kinases were 
further validated (Table S2 and S3). To understand if any of these kinases provide a 
mechanistic link to iron-induced STAT3 activity, luciferase reporter assays were performed. 
Interestingly, only CDK1 could potentiate the activation of STAT3 by IL6 (Figure S6B). We 
further confirmed that CDK1 could bind to iron in CRC-derived cell lines by Western blot 
analysis (Figure 6B). Furthermore, iron could bind to CDK1 from mouse colon tumor 
lysates (Figure 6C), and this binding was direct, as assessed using recombinant CDK1 
(Figure S6C). To further demonstrate that iron and CDK1 resulted in a biologically relevant 
response, kinase assays were performed in the absence or presence of iron. The data clearly 
demonstrates that iron was critical for CDK1 activity (Figure 6D). To further understand if 
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iron via CDK1 was important for STAT3 activation we performed STAT3-dependent 
reporter assays. The increase in STAT3 reporter activity that was driven by IL-6 was 
potentiated by CDK1 (Figure 6E). The addition of iron further increased the activity, 
whereas chelation by DFO completely abrogated CDK1 induced potentiation of STAT3 
activity. To assess if CDK1 is essential for iron and IL6 induced STAT3 activity, siRNA or 
CDK1/2 inhibitor (CDKi) Dinaciclib was used to inhibit CDK1 expression or function. In 
the STAT3 reporter assay, siRNA-mediated knockdown of CDK1 resulted in decreased 
STAT3 activity following IL6 treatment (Figure 6F). In addition, CDK1 siRNA attenuated 
IL6- and iron-mediated STAT3 activation as assesses by p-STAT3 in CRC-derived cell lines 
(Figure 6G and H). Consistent with the siRNA data, CDKi inhibited IL6- and iron-mediated 
STAT3 activation (Figure 6I and J). To understand the downstream JAKs that are critical for 
CDK1 potentiation, JAK1 and JAK2 were assessed (JAK3 had only minimal activity on the 
STAT3 reporter assay). CDK1 could potentiate JAK1- (but not JAK2-) STAT3 activity, 
whereas CDK1 siRNA reduced JAK1-dependent STAT3 activity on the STAT3 reporter 
assay (Figure 6K and L). This potentiation was shown to be iron-dependent as DFO 
treatment attenuated the increase (Figure 6M). Next, we performed a phospho-transfer assay, 
where we could monitor CDK1 mediated phosphorylation of JAK1 by a luminescence-based 
detection system. In the absence of iron, recombinant CDK1 did not increase 
phosphorylation of recombinant JAK1. However, the addition of iron increased this 
phosphorylation (Figure 6N). This provides direct evidence that iron is required for CDK1-
mediated JAK/STAT3 activity. To test the potential translational application of CDKi, 
patient-derived enteroids were treated with Dinaciclib. At the indicated doses CDKi did not 
affect the growth and cell proliferation of enteroids under iron-reduced conditions. However, 
the CDKi reduced the iron-enhanced cell growth and proliferation in both colon adenoma 
and adenocarcinoma-derived enteroids (Figure 6O). These data indicate that CDK1 is an 
important downstream pathway for iron in CRC.
Pharmacological inhibition of DMT1 decreases colon tumor growth
To study whether DMT1 could be pharmacologically inhibited in colon tumors in vivo a 
DMT1-specific inhibitor (DMT1i) XEN 602 was utilized (Cadieux et al., 2012). DMT1i 
dose-dependently decreased iron absorption in a hyper-absorption mouse model in vivo 
(Figure S7A). To study whether DMT1 could be pharmacologically inhibited in colon 
tumors in vivo, CDX2ERT2 ApcF/+ mice with established colon tumors were treated with 
DMT1i. Pharmacological inhibition of DMT1 significantly reduced tumor number and 
tumor burden (Figure 7A). Moreover, p-STAT3 activation, tumor iron accumulation, and 
tumor cell proliferation were also decreased following DMT1i treatment (Figure S7B and 
S7C). To test the translational application, patient-derived enteroids were assessed. DMT1i 
did not affect the growth and cell proliferation of patient-derived enteroids under iron-
reduced conditions, but inhibited the iron-induced cell growth and proliferation in both 
colon adenoma (Figure 7B) and adenocarcinoma-derived enteroids (data unshown). To 
conclusively show that DMT1 is an effective therapeutic target in CRC, human tumor 
enteroids were intrarectally implanted in NOD/SCID mice. These tumors can engraft in the 
mouse colon, which is demonstrated by a mini colonoscope (Figure 7C). Moreover we 
confirmed the engrafted tumors by a human specific DMT1 staining at 2 weeks following 
intrarectal injections, which showed a robust signal in the engrafted tumor, but not in mouse 
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colon tumors (Figure 7D). Following engraftment at 2-weeks the mice were treated with 
DMT1i for an additional 2-weeks. The colons were stained with hDMT1 and PCNA to 
clearly indicate proliferation in our engrafted tumors. DMTi significantly and specifically 
decreased the tumor cell proliferation as observed by quantitating cells positive for hDMT1 
and PCNA (Figure 7E). This not only establishes the role of DMT1 as a therapeutic target, 
but we have optimized a patient-derived orthotopic CRC model. Together, the findings 
highlight a DMT1-Fe2+-CDK1-JAK1-STAT3 signaling axis essential in colorectal tumor 
growth (Figure 7F).
Discussion
Through loss- and gain- of function experiments we demonstrate that increased intratumoral 
iron is essential for colon tumorigenesis. Our studies and data offer in-depth insights into a 
key signaling axis initiated by tumor epithelial HIF-2α transcription, leading to an increase 
in apical iron transporter DMT1. Apical transport of iron leads to direct activation of CDK1, 
which in turn promotes the initiation and sustained signaling of the oncogenic JAK1-STAT3 
pathway. Data from epidemiological studies, mouse models, and cell lines have supported 
the critical role of iron in CRC (Cross et al., 2010; Merk et al., 1990; Nelson, 2001; Osborne 
et al., 2010; Zacharski et al., 2008; Radulescu et al., 2012; Xue et al., 2012; Brookes et al., 
2006; Seril et al., 2003). High dietary iron intake or patients with iron overload have 
increased risk for CRC (Cross et al., 2010; Osborne et al., 2010). Patients with lower iron or 
in mouse models treated with low iron diet exhibit a decrease in CRC (Ashmore et al., 2015; 
Bastide et al., 2015; Nelson, 2001). The majority of previously described mouse genetic 
models of intestinal tumorigenesis mainly develop small intestinal adenoma (Johnson and 
Fleet, 2013). The small intestine and colon vastly differ with respects to the relative levels of 
luminal iron (Blachier et al., 2007). Due to these issues, it has been difficult to fully 
understand the role and mechanisms of local and systemic changes in iron homeostasis in 
colon tumor progression in mice. Based on the use of colon-selective mouse tumor models, 
colon-derived cell lines and patient-derived enteroid models, the findings presented here 
offer a clear and convincing support for the role of iron in colon tumor development and 
progression. The present work demonstrates that STAT3 is an essential link between high 
iron levels and CRC progression. STAT3 signaling is frequently activated in malignant cells 
and capable of inducing a large number of genes that are crucial for promoting tumor cell 
proliferation, reducing cell apoptosis, increasing tumor invasion and suppressing anti-tumor 
immunity (Yu et al., 2009). Numerous carcinogens, growth factors and inflammatory 
cytokines activate STAT3. A well-characterized pathway for STAT3 activation in CRC is 
mediated via JAK family tyrosine kinases, following stimulation of cells by inflammatory 
cytokines, such as IL6 and IL11 (Putoczki et al., 2013). In mouse models, CRC-derived cell 
lines and CRC patients, we have shown that iron activates STAT3 signaling, which is 
essential for progression of colorectal tumors under high dietary iron. These data 
demonstrate high iron is sufficient in activating STAT3 signaling. Moreover, iron is also 
essential in the activation of STAT3 by IL6 in cell lines and tumors. Following iron chelation 
or disruption of DMT1 in the tumors, IL6-induced STAT3 signaling was significantly 
attenuated.
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JAKi completely abolished iron- and DMT1-induced STAT3, demonstrating that iron-
mediated activation of STAT3 is dependent on JAKs. To identify pathways which link iron to 
STAT3 signaling in tumor epithelium, an unbiased proteomic approach was utilized to 
identify proteins that could directly bind to iron. We believe ferrous iron to be the main form 
of iron that acts as a signaling co-factor, since ferrous iron is the preferred form to be 
transported intercellular via DMT1. However, free iron is very low in cells and metalation of 
kinase substrates could be through a chaperone-mediated mechanism. The iron chaperone 
poly(rC) binding proteins (PCBPs) can bind to ferrous iron with low micromolar affinity and 
deliver iron to substrates (Shi et al, 2008). Future work is needed to better understand the 
mechanisms of iron mobilization to substrates identified in the present work. Here we offer 
findings indicating that iron may be a key and direct signaling co-factor. CDK1 was one of 
the 17 protein kinases that could bind with iron. CDK1 is a kinase important in promoting 
cell mitosis (Satyanarayana and Kaldis, 2009). CDK1 activity is highly elevated in colorectal 
tumor tissues compared to normal tissues (Salh et al., 1999) and predicts distant metastasis 
risk in stage II CRC (Zeestraten et al., 2012). JAK1 contains 8 canonical CDK1 
phosphorylation motifs (Ser/Thr–Pro–X–Lys/Arg) (Tak et al., 2006; Xue et al., 2008), and 
future studies are needed to validate the importance of these sites in JAK1-STAT3 signaling. 
The direct regulation of CDK1 activity by iron provides mechanistic data integrating iron 
levels to cell cycle regulation, and is consistent with previous work, demonstrating an 
essential role of iron in regulating cell cycle progression (Le and Richardson, 2002; 
Nurtjahja-Tjendraputra et al., 2007). Similar integration of divalent metals to cell 
proliferation has been described for copper. Copper can directly bind MEK1 and this 
interaction is essential for activation of ERK1/2 (Brady et al., 2014). Currently, it is not clear 
if direct binding of iron to CDK1 is essential to increase activity. We are assessing 
mechanisms and motifs required for iron to bind to proteins. Phosphorylation is the most 
commonly studied post-translational modification of proteins, with a major role in mediating 
extracellular and intracellular signals and enabling cells to adapt to a rapidly changing 
environment. The significance of iron in the activation of the other kinases and proteins in 
addition to CDK1, needs to be determined and future studies will focus on understanding 
specific pathways regulated by iron.
The present work identifies a pathway by which iron can contribute to CRC progression. 
However, previous work has demonstrated that iron is critical in WNT signaling, DNA 
synthesis, ROS-induced cell damage, and P53 modulation (Brookes et al., 2008; Dixon et 
al., 2012; Dixon and Stockwell, 2014; Le and Richardson, 2002; Shen et al., 2014). Studies 
to discern the contribution of each pathway are required to understand their importance and 
the possible crosstalk among pathways. However, the present work clearly indicates an 
important role of DMT1 in regulating intratumoral iron levels. Interestingly, DMT1 has no 
apparent role in regulating normal colon epithelial homeostasis, demonstrating that intestinal 
epithelial cells can acquire iron for local use through transferrin-bound iron or through other 
iron transporters such as SLC39A14 (also know as ZIP14) (Jenkitkasemwong et al., 2015). 
The tumor epithelium is highly dependent on DMT1 for iron acquisition and growth. 
Disruption of DMT1 in the small intestine leads to progressive and severe anemia (Gunshin 
et al., 2005). However, using a DMT1i we demonstrated a therapeutic dosing scheme that 
results in decrease of colon tumors and tumor cell proliferation with minimal systemic 
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effects. Moreover, the possibility of combining DMT1i with a colon-specific delivery agent 
may even further increase the efficacy of DMT1 inhibition for possible CRC prevention and 
treatment.
In conclusion, our findings support the notion that local depletion of iron, inhibition of 
DMT1 function and iron influx, and/or inhibition of JAK-STAT3 activity in colon tissues 
might be powerful therapeutic approaches for the treatment of CRC and perhaps even 
prevention in certain subsets of patients at elevated risk of CRC.
EXPERIMENTAL PROCEDURES
Patient-derived colorectal tumor enteroids
Patient-derived colorectal tumor enteroids were generated as previously described (Dame et 
al., 2014).
Animals and treatments
Full details on the mouse lines and treatments are found in Supplemental Information. All 
animal studies were approved by the University Committee on the Use and Care of Animals 
at the University of Michigan.
Quantitative real-time reverse transcriptase PCR
mRNA was measured by Real Time RT-PCR (Life Technologies, Carlsbad, CA; primers 
listed in Table S1). Quantification cycle (Cq) values were normalized to β-actin and 
expressed as fold difference from controls.
Determination of serum and tissue iron, tissue ROS
Serum and tissue non-heme iron was quantitated as previously described (Anderson et al., 
2013). ROS was determined using dichlofluorescein diacetate (DCF).
High-throughput screening
HCT116 cells overexpressing HIF-2α and DMT1 promoter luciferase were tested with the 
siRNA druggable target screen. 230 genes were identified to inhibit more than 90% of 
HIF-2α-induced DMT1 promoter luciferase activity. Genes that demonstrated increased 
expression in CRC tissues and predicted decreased tumor free survival were validated with 
independent siRNAs.
Microarray
Microarray analysis was done as previously described (Xue et al., 2014). The full data set is 
available on the Gene Expression Omnibus database accession number GSE65104.
Proteomic analysis of the iron interactome
Fe2+ conjugated beads or metal-free beads were obtained from Affiland (Liege, Belgium). 
Transferrin or lysates from HCT116, SW480 cell or mouse colon tumor were incubated with 
Fe2+ conjugated beads or metal-free beads for 2 hours and washed three times with EDTA-
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free Triton lysis buffer. Proteins were eluted and used for Westerns or trypsin digestion and 
mass spectrometry analysis.
Data analysis
Data are presented as individual data points and error bars represent the standard error of the 
mean (SEM). P values were calculated by independent t test, paired t-test, one-way ANOVA, 
Dunnett t test, and two-way ANOVA. Organoid size, immunofluorescence staining and 
western blot analysis were quantified with Image J.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Iron accumulation in CRC is dependent on HIF-2α-induced iron 
importer DMT1.
• Genetic disruption or pharmacological inhibition of DMT1 reduces 
CRC.
• Iron-CDK1 interaction activates JAK1-STAT3 signaling in CRC.
• Inhibition of CDK1 or STAT3 antagonizes iron-driven cell proliferation 
in CRC.
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Figure 1. DMT1 is overexpressed in CRC
(A) Studies of iron regulatory genes determined by RNA-Seq in the TCGA database and (B) 
gene expression analysis of DMT1 by qPCR in 8 pairs of primary human CRCs and adjacent 
normal tissues collected at University of Michigan (UM). (C) Quantification of DMT1 
staining and (D) representative fluorescent microscopy in CRCs and adjacent normal tissues 
(left), and confocal images demonstrating apical colocalization of DMT1 and E-Cadherin 
(E-cad) co-staining (right). *p<0.05, **p<0.01 and ***p< 0.001 and error bars represent 
SEM.
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Figure 2. Colon-selective disruption of DMT1 decreases sporadic and colitis-associated colon 
tumors
(A) Gene expression of Dmt1 in CRCs and their adjacent normal tissues, (B) tumor number 
and burden, (C) gross image and H&E staining, and (D) representative images and 
quantification of Ki67 staining of CRCs from CDX2 Dmt1F/F/ApcF/+ mice and their 
littermate controls at 3 months old. (E) Gene expression of Dmt1 in CRCs and their adjacent 
normal tissues, (F) tumor number and burden, (G) quantification of Ki67 staining of colon 
tumors from CDX2ERT2 Dmt1F/F/ApcF/+, CDX2ERT2 Dmt1F/+/ApcF/+ mice and their 
littermate controls. *p<0.05, **p<0.01 and ***p< 0.001 and error bars represent SEM. See 
also Figure S1 and S2.
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Figure 3. HIF-2α is essential in the transcriptional regulation of DMT1
Dmt1 expression in CRCs and adjacent normal tissues from Vil Hif-2αF/F/Apcmin/+ mice 
(A), CDX2 Hif-2αF/F/ApcF/+ mice (B) and their littermate controls. (C) Tumor number, (D) 
gross image, H&E and enhanced Perls’ staining of CRCs, from CDX2 Hif-2αF/F/ApcF/+, 
CDX2 Hif-2αF/+/ApcF/+ mice and their littermate controls at 3 months old. (E–H) DMT1 
promoter luciferase assay in HCT116 cells. (I) High throughput screening for genes critical 
for DMT1 activation. *p<0.05, **p<0.01 and ***p< 0.001 and error bars represent SEM.
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Figure 4. Inflammatory responses are increased in iron-driven colon tumorigenesis
(A) Enrichment plot and heatmap derived by gene set enrichment analysis (GSEA) for genes 
in regulation of immune response and inflammatory response. (B) Gene expression of 
inflammatory genes in colon tumors (T) and adjacent normal tissues (N) from CDX2; 
Dmt1F/F/ApcF/+ mice and their littermate controls. *p<0.05, **p<0.01and ***p< 0.001 error 
bars represent SEM. See also Figure S3.
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Figure 5. Iron is essential for STAT3 activation in colon tumorigenesis
(A) TCGA reverse phase protein array (RPPA) analysis based on iron transporter expression 
in tumor tissues (high iron transporters, n=85; low iron transporters, n=531). (B) Western 
blotting analysis of in colon tumors (T) and adjacent normal tissues (N) from CDX2 
Dmt1F/F/ApcF/+ mice and littermate controls. (C) Immunofluorescence staining and 
quantification for p-STAT3 in CRCs from CDX2ERT2 Dmt1F/F/ApcF/+ mice (n=3). (D) 
STAT3 activity reporter assay in cells transfected with empty vector (EV), JAK1, JAK2 or 
JAK3 and treated with deferoxamine (DFO) 100 μM or control for 24 hours. Western blot 
analysis in HCT116 or SW480 cells treated (E) with DFO (100 μM) and IL6 (10 ng/mL) for 
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24 hours, or (F) with ferrous sulfate (FS, 100 μM) and JAK1/2 inhibitor (JAKi, 3 μM 
Ruxolitinib) for 24 hours. (G) Western blot analysis in HCT116 or HEK293T stable cells 
overexpressing DMT1 or parental controls treated with JAKi (3 μM) for 24 hours. (H) 
Western blot analysis in HCT116 or SW480 cells treated with FS (0 or 100 μM) and STAT3 
inhibitor (STAT3i, 0 or 100 μM S3I-201) for 24 hours. (I) Representative gross image of 
CRCs, (J) tumor number, size, burden and number grouped by size from CDX2ERT2 ApcF/+ 
mice maintained on regular iron diet (35 mg/kg iron, 35 Fe) or high iron diet (1000 mg/kg 
iron, 1000 Fe). (K) STAT3 expression level in stable adenoma enteroids with STAT3 
knockdown (shSTAT3) or scramble shRNA (shScr). (L) Representative bright-field images 
and quantification of enteroid size and Ki67 staining of adenoma enteroids grown in iron-
reduced RPMI media or RPMI media supplemented with FS 100 μM for 7 days. *p<0.05, 
**p<0.01 and ***p<0.001. ##p<0.01 compared with FS treated shScr stable adenoma 
enteroids. Errors bars represent SEM. Western blot data was quantitated and the values 
above the blots represent p-STAT3/STAT3. See also Figure S4 and S5.
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Figure 6. Iron-dependent CDK1 kinase activity is critical for JAK-STAT3 activation
(A) Schematic diagram for identification of Fe2+ binding proteins with LC-MS/MS based 
proteomics analysis. (B) Immunoblot analysis of proteins pulled down (PD) by Fe2+ or 
empty beads in HCT116 cells transfected with HA-tagged CDK1 or empty vector (EV). (C) 
Immunoblot analysis of CDK1 protein PD by Fe2+ or empty beads from mouse colon 
tumors lysates. (D) Kinase assay assessing histone H1 (H1) phosphorylation by purified 
recombinant (r) CDK1 in the presence or absence of FS 10μM. (E) STAT3 activity reporter 
assay in HCT116 cells transfected with EV or CDK1 and treated with IL6 10 ng/mL, FS 100 
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μM, DFO 100 μM or vehicle control for 24 hours. (F) STAT3 activity reporter assay in 
HCT116 cells transfected with 50 nM siRNA for CDK1 (siCDK1) or scrambled control 
(siScr) and treated with vehicle control or IL6 10 ng/mL. Western blot analysis in HCT116 
or SW480 transfected with siCDK1 for 24 hours and then treated with (G) FS or (H) IL6 for 
24 hours. Western blot analysis in HCT116 or SW480 cells treated with (I) FS and CDK1/2 
inhibitor (CDKi, 0 or 10 nM Dinaciclib), or (J) with IL6 and CDKi for 24 hours. STAT3 
activity reporter assay in HCT116 cells transfected with (K) EV, CDK1, JAK1 or JAK2, (L) 
siCDK1, siScr and/or JAK1, or (M) EV, CDK1, JAK1 and/or DFO for 24 hours. (N) 
Phospho-transfer assay assessing JAK1 phosphorylation by rCDK1 in the presence of FS (0 
or 10 μM). (O) Representative bright-field images and quantification of enteroid size and 
Ki67 staining of adenoma enteroids grown in iron-reduced RPMI media or RPMI media 
supplemented with FS 100 μM after treatment with CDKi (0 or 10 nM) for 7 days. *p<0.05, 
**p<0.01 and ***p<0.001. ##p<0.01 compared with iron-reduced conditions. Error bars 
represent SEM. Western blot data was quantitated and the values above the blots represent p-
STAT3/STAT3. See also Figure S6, Table S2 and S3.
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Figure 7. Pharmacological inhibition of DMT1 decreases growth of colon tumors
(A) Tumor number and burden from CDX2ERT2 ApcF/+ mice orally administered with 50 
mg/kg DMT1i, or vehicle. (B) Representative bright field images, and quantification of size 
and Ki67 staining of adenoma enteroids grown in iron-reduced RPMI media or RPMI media 
supplemented with FS 100 μM after treatment with DMT1i (0 or 3 μM) for 7 days. (C) 
Intrarectal implantation of adenoma enteroid in NOD/SCID mice visualized by endoscopy 
examination. Dotted line represents the established adenoma xenograft. (D) 
Immunofluorescent staining of a mouse colon tumor and adenoma xenograft from human 
specific DMT1 antibody (hDMT1). (E) Immunofluorescent staining and quantification of 
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co-localization of hDMT1 and PCNA for established tumors from human adenoma enteroids 
grown in NOD/SCID mice for 2 weeks and then mice orally administered with 50 mg/kg 
DMT1i, or vehicle for 2 weeks. (F) Proposed mechanism for iron-driven colon 
tumorigenesis. Fe2+ is transported by DMT1 into intestinal epithelial cells and binds with 
CDK1, which increases CDK1 kinase activity to phosphorylate JAK1 kinase and activates 
STAT3 signaling pathway for tumor growth. *p<0.05 and **p<0.01 and error bars represent 
SEM. See also Figure S7.
Xue et al. Page 26
Cell Metab. Author manuscript; available in PMC 2017 September 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
